Bone H G, Zerwekh J E, Britton F, Pak C Y
J Urol. 1979 May;121(5):568-71. doi: 10.1016/s0022-5347(17)56883-4.
The effect of treatment of renal stone formation with 5 to 20 mg./kg. per day oral disodium ethane-1-hydroxy-1,1-diphosphonate for up to 30 months was examined in 12 patients with active renal (calcium) stone disease. The over-all incidence of stone passage decreased from 17.8 stones per year per patient before treatment to 7.7 stones per year per patient during therapy. Of the 12 patients 7 passed fewer stones or no stones during treatment. However, the incidence of stone passage was not changed substantially by disodium ethane-1-hydroxy-1,1-diphosphonate in 5 patients. Symptoms of muscle weakness and pain in the back, hips and shoulders occurred in 3 patients during treatment, 2 patients had an increase in serum alkaline phosphatase and 1 patient had a decrease in bone density. Although disodium ethane-1-hydroxy-1,1-diphosphonate may be clinically useful to manage calcium urolithasis in certain patients its over-all use is limited because of its ineffectiveness in some patients and owing to its potential to induce osteomalacia.
对12例活动性肾（钙）结石病患者进行了研究，观察每日口服1,1-二羟基乙二膦酸二钠5至20毫克/千克、持续30个月对肾结石形成的治疗效果。结石排出的总体发生率从治疗前每位患者每年17.8块降至治疗期间每位患者每年7.7块。12例患者中有7例在治疗期间排出的结石减少或未排出结石。然而，1,1-二羟基乙二膦酸二钠对5例患者的结石排出发生率没有实质性改变。3例患者在治疗期间出现肌肉无力以及背部、臀部和肩部疼痛的症状，2例患者血清碱性磷酸酶升高，1例患者骨密度降低。尽管1,1-二羟基乙二膦酸二钠在某些患者中对治疗钙尿石症可能具有临床实用性，但其总体应用受到限制，原因在于它对一些患者无效且有诱发骨软化症的可能性。
